Cabaletta BioCABA
Recorded

Cabaletta Bio 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Yatin SunejaSenior Biotech Analyst

Welcome to Third Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the Senior Biotech Analysts here at Guggenheim. It is my pleasure to welcome our next presenting company, Cabaletta. We have a few executives from the company here with us. We have Steve Gavel, who is the Chief Commercialization Officer, Anup Marda, who is the Chief Financial Officer. We have Arun Das, who is the Chief Business Officer. Gentlemen, thank you so much for your time. I think you just came here from ACR, so I would love to sort of get a little bit of an update there. Perhaps maybe make some opening comments and tell us some of the learnings and the data that were presented at ACR, and then I have prepared a little Q&A, and then we will go into that.

Arun DasChief Business Officer

That sounds great, Yatin. First of all, thanks for having us. It is a pleasure to be here. Just as a brief, very quick reminder for folks, we are Cabaletta, developing CAR T therapies for patients with autoimmune disease. That is what we have been since the founding of the company in 2018. Like you said, just coming off a really important medical meeting at ACR where we were able to showcase both safety and efficacy data across the portfolio of indications that rese-cel, our lead CD19 CAR T program, is being evaluated in. I think the summary of that data, and excited to go into more detail, is we are seeing, based on this data, the vision for rese-cel that we had four or five years ago come into reality and sharper focus.

Arun DasChief Business Officer

Across the portfolio, the choices that we made years ago around a well-characterized routine manufacturing process, weight-based dosing, a 4-1BB co-stimulatory domain, a fully human CAR, these are the choices we made back in 2022, 2023, and the data that we have showcased, I think, are now highlighting what type of profile those choices yielded. From a safety perspective, we presented 70 patients' worth of data across a number of autoimmune diseases, all patients treated with the same single weight-based dose of rese-cel, and we see a low frequency of CRS, a low frequency of ICANS. 94% of patients have no CRS or grade 1 CRS, a fever. 96% of patients have no ICANS. There is no IEC-HS observed across any patient that has been treated, reported to date.

Arun DasChief Business Officer

We think those choices are really crucial ones to help yield the profile we have that we think allows us to make CAR T a reality in the autoimmune space. On the efficacy side of things, we were able to present data across a number of different rheumatology conditions. Dermatomyositis, where at one year, patients who discontinued their immunomodulators prior to infusion of rese-cel at one year saw major or moderate TIS responses. Again, off all immunomodulators for the duration of follow-up. Most of those patients were also off steroids. In lupus nephritis, we were able to see 100% of patients who obtained a repeat kidney biopsy achieve DORIS remission at their latest follow-up visit, and these follow-ups were anywhere from six months to two years. Again, discontinuing immunomodulators before and staying off those immunomodulators, and again, either off steroids or on low-dose steroids.

Arun DasChief Business Officer

In systemic sclerosis, we were able to see patients also followed out to one year, 70% of them hitting the very stringent ACR-CRISS 50 standard composite endpoint across a number of different domains. It is consistent and fairly reliable, the ability to discontinue patients off their immunomodulators, give them a single dose of rese-cel that is a weight-based infusion, and then see them allowed to stay off those medicines and oftentimes discontinue their steroids as well. It is a really exciting time. Thank you for asking. Very good.

Yatin SunejaSenior Biotech Analyst

Let's, I think there were like three key presentations, at least according to me. Maybe we can dive a little bit deeper into all these presentations. For the myositis study, obviously, there was the durability that was presented, but I think to me, what I saw was that not only your product is providing durability, but there is a depth because you were able to capture one additional patient. Just talk about the durability and depth of responses you are seeing with the product in myositis particularly, and how does that read through into the pivotal program that you're running?

Arun DasChief Business Officer

Yeah. I think the most important connection between the phase I/II and the registrational program in myositis is, it is a very similar program. It is similar sites, the same dose of drug, similar patient characteristics from an inclusion/exclusion criteria that allow us to take that phase I/II data and have increasing confidence in the way that we've designed the registrational study. What we reported from the phase I/II data was the one-year outcomes of patients. Like you said, we saw actually one patient who at the week 16 time point had a temporary sort of blip in their total improvement score, but because that patient never received a dose of immunomodulators for the duration of follow-up, they continued to be followed and counted as a potential, and they could count as a potential responder in the analysis.

Arun DasChief Business Officer

At one year, with that patient being off immunomodulators for the duration of follow-up, they actually achieved the endpoint that we would consider as being most important in this space, which is at least a moderate TIS response, again, while being off immunomodulators and either off steroids or on low-dose steroids. It really highlights the fact that the emerging data seem to show the potential for rese-cel to actually have deepening responses over time in patients who receive this one-time infusion.

Yatin SunejaSenior Biotech Analyst

Got it. I will come back to the LN and SSc, but let's conclude the myositis discussion because that's where the pivotal program is running, right? How is the enrollment there? What is the I think you updated the guidance in terms of when the data is going to be expected. Talk about that. What are your expectation? What will be actually disclosed? If you have to look at this phase I data, it seems like you really cleared the bar by wide margin, but just put all of that in perspective for us.

Arun DasChief Business Officer

Yeah. For enrollment, let me turn it over to Anup, then back to me for the data. Anup, do you want to talk about enrollment?

Anup MardaCFO

Yeah, sure. In the last few weeks, Yatin, we've seen multiple patients enroll in our myositis pivotal study. We've seen the screening pipeline increase significantly as well. I think what you're alluding to, in the summertime, we did see a slowdown in the study, which we believe was caused by the adverse safety events, which other cell therapy players had. As soon as those kind of adverse events came to light, our Chief Medical Officer, David Chang, and his team reached out to all of our investigators, providing them with the information, clinical and safety, which Arun had mentioned earlier, on rese-cel, reminding them of kind of the weight-based dosing, the well-characterized manufacturing process, et cetera. We received significant feedback from them as well. We had good discussions with them, following our reach out to them.

Anup MardaCFO

Based on the uptick in enrollment that we see in the screening pipeline and the discussions we've had with the investigators, we moved our guidance to the first quarter of 2028 for BLA submission, and we feel good about that. The good news is we have the cash to get us to the first quarter of 2028 as well, and we extended our cash runway as well. That's kind of where we stand from an enrollment perspective. I will pass it back to Arun to answer the rest of your question.

Arun DasChief Business Officer

Yeah. So on the data front, I think, and just reflecting on what we heard at ACR, I think it was fascinating because this year's ACR was really the first major meeting where I felt like there was a transition between CAR T is a novel modality that is showcasing some interesting data, to this class could be a real class of drugs for the rheumatology community to address patients with meaningful autoimmune disease. So the difference being the conversations around what patient should we be treating, how do you select the right patient to receive CAR T therapy, because the experience is growing. Even in our phase I/II study, we had investigators from multiple different sites enroll patients, treat patients, and we're seeing that enthusiasm, that experience really feed forward into what the registrational program looks like.

Arun DasChief Business Officer

The similarities of the design from the phase I/II to the registrational, I think, are key in enabling our view that these outcomes that we're seeing in the phase I/II have a lot of There's a lot of relation potentially to the phase III study. Even, and I think this is worth mentioning, we recently had an FDA interaction where from that interaction, we're now planning to submit the phase I/II data, the one-year data of which we presented a couple days ago, but that phase I/II data in our BLA submission for myositis, so that it is able to potentially count for durability of response following a single dose of rese-cel. Those are patients whose data we may have two or three years worth of which by the time we submit the BLA.

Arun DasChief Business Officer

Yeah. Very important in our discussions with a number of different stakeholders.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day